TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03260400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a bipolar percutaneous intramuscular electromyography electrode
Description: The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a bipolar percutaneous intramuscular electromyography electrode
Description: The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
Study: NCT03773783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Button and Bead appliance
Description: Button and Bead appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block appliance
Description: Twin Block appliance
Study: NCT03395678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
Study: NCT03801252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: intravenous drugs used as prophylactic antibiotics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: prophylactic antibiotic
Study: NCT02324543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT03778632

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individualized desensitization exercises
Description: implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
Study: NCT03395678

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional non-ablative 1,540nm laser
Description: The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
Study: NCT03778632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized desensitization exercises
Description: implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
Study: NCT01035788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Behavioral Conjoint Therapy
Description: This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
Study: NCT03728088

Intervention type: OTHER
Intervention: Rating scales concerning non-technical attributes

Intervention type: OTHER
Intervention: Rating scales concerning non-technical attributes

Intervention type: OTHER
Intervention: Rating scales concerning non-technical attributes
Study: NCT01035788

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCT for PTSD - Communication Skills
Description: This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
Study: NCT00077194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Study: NCT00657566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duration of antibiotics
Description: 4 +/- 1 days of antibiotics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: duration of antibiotics
Description: active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
Study: NCT02865291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForConti device
Study: NCT03226093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction
Description: The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
Study: NCT00646295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
Description: Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
Study: NCT02267486

Intervention type: OTHER
Intervention: Standard therapy of Alzheimer Dementia (AD)

Intervention type: OTHER
Intervention: Observation
Study: NCT00622193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Description: 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Description: 100 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study: NCT02704962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: full-dose olanzapine
Description: trifluoperazine 5mg/d
Study: NCT03588468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrophysiological biomarkers
Description: Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
Study: NCT02704962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full-dose olanzapine
Description: trifluoperazine 5mg/d
Study: NCT00787111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine (prozac)
Description: Formulation: ODT
Study: NCT03429218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0184
Description: Oral dose once weekly for 4 weeks
Study: NCT00162773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
Study: NCT03588468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiological biomarkers
Description: Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electrophysiological biomarkers
Description: Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI biomarkers
Description: T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI biomarkers
Description: T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MRI biomarkers
Description: T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
Study: NCT01603147

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: saline 225 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch-mAb7f9
Description: The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
Study: NCT00487591

Intervention type: DRUG
Intervention: Omacor (omega-3-acid ethyl esters)plus simvastatin
Description: Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)

Intervention type: DRUG
Intervention: simvastatin plus placebo
Description: simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
Study: NCT01400048

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aloe vera effervescent tablet (AVH200)
Description: 250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 60mg Ascorbic acid
Study: NCT00250484

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: 1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
Study: NCT01961492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: A single fecal microbiota transplantation through colonoscope
Study: NCT04464460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-671
Description: TAK-671 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-671
Description: TAK-671 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-671 Placebo
Description: TAK-671 placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-671 Placebo
Description: TAK-671 placebo-matching intravenous infusion.
Study: NCT02324543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Twice a day orally on days 1 through 14 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Twice a day orally on days 1 through 14 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Twice a day orally on days 1 through 14 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Twice a day orally on days 1 through 14 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Twice a day orally on days 1 through 14 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Twice a day orally on days 1 through 14 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT03286504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANMI - Cohort Care
Description: FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
Study: NCT06255483

Intervention type: OTHER
Group type: OTHER
Intervention: Osteoperiosteal pedicled clavicular flap for mandibular and facial bone reconstruction
Description: A clavicular flap with a vascular supply based on the transverse cervical artery which receives a reverse blood supply from the ascending cervical artery. This vascular pattern is reliable because of the existence of the sub-occipital microvascular network named the  Bosniak node .
Study: NCT01965795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Coffee Fruit Concentrate (WCFC)
Description: Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrim
Description: Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
Study: NCT03137368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane Tablets
Description: drug therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ovarian function suppression/ablation
Description: Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ovarian function suppression/ablation
Description: Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6*10 gene test
Description: CYP2D6\*10 gene test

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2D6*10 gene test
Description: CYP2D6\*10 gene test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: drug therapy
Study: NCT01007877

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Red Bull Energy drink
Description: During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red Bull Energy drink
Description: During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Bull Energy drink
Description: During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
Study: NCT04585542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Nonspecific laxative comparison group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Polystyrene Sulfonate Oral Suspension [SPS]
Description: Potassium binder to treat hyperkalemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Potassium binder to treat hyperkalemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Potassium binder to treat hyperkalemia.
Study: NCT02321904

Intervention type: PROCEDURE
Intervention: Corneal Confocal Microscopy
Description: Close-up pictures of the front part of the eye (the cornea)

Intervention type: PROCEDURE
Intervention: Corneal Confocal Microscopy
Description: Close-up pictures of the front part of the eye (the cornea)

Intervention type: PROCEDURE
Intervention: Nerve Conduction Studies
Description: The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
Study: NCT00162773

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150-375 milligrams depending on body weight and serum IgE.
Study: NCT02321904

Intervention type: PROCEDURE
Intervention: Nerve Conduction Studies
Description: The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.

Intervention type: PROCEDURE
Intervention: Quantitative sensory testing
Description: Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.

Intervention type: PROCEDURE
Intervention: Quantitative sensory testing
Description: Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.

Intervention type: PROCEDURE
Intervention: Neuropathy Symptom Score
Description: A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
Study: NCT02493179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serodase 5 mg
Description: Serodase 5mg two tablets three times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two tablets three times per day
Study: NCT02321904

Intervention type: PROCEDURE
Intervention: Neuropathy Symptom Score
Description: A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.

Intervention type: PROCEDURE
Intervention: Clinical nerve examination
Description: Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.

Intervention type: PROCEDURE
Intervention: Clinical nerve examination
Description: Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
Study: NCT02756520

Intervention type: OTHER
Intervention: Observational study: Supplemented protein-restricted diet
Description: Observational study: Supplemented protein-restricted diet
Study: NCT02497014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Stent
Description: Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 Stents
Description: Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion.
Study: NCT01255020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-Keto Acid with restricted protein diet
Description: α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus restricted protein diet
Description: placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d.